id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-M-0796-0002,FDA,FDA-2011-M-0796,Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications,Notice,Notice of Approval,2012-03-16T04:00:00Z,2012,3,2012-03-16T04:00:00Z,,2012-03-16T14:10:08Z,2012-06390,0,0,0900006480fd8b19
FDA-2011-M-0796-0001,FDA,FDA-2011-M-0796,"Abbott Vascular, Inc., Xience Prime and Xience Prime LL Everolimus-Eluting Coronary Stent System, P110019 - Premarket Approval",Other,Approval,2011-12-15T05:00:00Z,2011,12,2011-12-15T05:00:00Z,,2011-12-15T22:04:42Z,,0,0,0900006480f670d8